COMPASS Pathways (CMPS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Mental Healthsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 36.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.79% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results
- Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress
- Compass Pathways Appoints Kelley Boucher as Chief People Officer
- Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
- Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
- Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Investigating hierarchical control among functional networks disrupted by opioid use disorder using effective connectivity. — Imaging Neurosci (Camb) 2026 PMID 42770093
- Refining the young mania rating scale: Accelerating development of psychopathology measures joint ISCTM/ECNP bipolar working group consensus. — J Affect Disord 2026 Sep 19 PMID 42762875
- Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper. — NPP Digit Psychiatry Neurosci 2026 Sep 18 PMID 42760290
- Remission status in persistent depressive disorder following acute treatment with psychotherapy plus medication or medication alone: A 2-year naturalistic follow-up. — J Affect Disord 2026 Sep 13 PMID 42732834
- Improving access to antipsychotic medications for schizophrenia in Ethiopia, Nigeria, Rwanda, and South Africa: an evidence-based global consensus. — Lancet Psychiatry 2026 Oct PMID 42716058
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for COMPASS Pathways.
Full CMPS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.